Results (4236)
D-SOLVE Clinical Cohorts
First published:
24/03/2025
Germany
Italy
Romania
Sweden
Data source
Human
BiobankDisease registryHospital outpatient visit recordsEuropean Venous Registry
First published:
24/03/2025
European Union
Norway
Portugal
Sweden
Switzerland
Türkiye
United Kingdom
Data source
Human
Disease registryA Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) (STRIVE)
Australia
Austria
Czechia
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Norway
Portugal
Puerto Rico
Slovakia
Spain
Sweden
United States
EU PAS number:
EUPAS30576
First published:
24/03/2025
StudyFinalised
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
United Kingdom
EU PAS number:
EUPAS13616
First published:
24/03/2025
StudyFinalised
Pan European Prospective Observational Study of Fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World, PEARL study
Belgium
Czechia
Denmark
Finland
Greece
Italy
Netherlands
Norway
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS35111
First published:
24/03/2025
StudyPlanned
TIMESPAN
Australia
Denmark
Germany
Hong Kong
Iceland
Ireland
Italy
Netherlands
Norway
Spain
Sweden
United Kingdom
United States
First published:
21/03/2025
Network
Radboud university medical center (Radboudumc)
Netherlands
First published:
21/03/2025
InstitutionEducational InstitutionHospital/Clinic/Other health care facilityENCePP partner
Comparative Effectiveness of Sotorasib Versus Docetaxel Monotherapy in Second Line and Beyond (2L+) Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in the Cancer Analysis System Database in England (20240164)
United Kingdom
EU PAS number:
EUPAS1000000405
First published:
20/03/2025
StudyOngoing
The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS42767
First published:
20/03/2025
StudyOngoing
Post-Authorization Safety Study to Assess the Effectiveness of the Newly Implemented Risk Minimization Measures for Topiramate: Drug Utilization Study
France
Germany
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000494
First published:
20/03/2025
StudyPlanned
DEN-401: The Association Between Prior Exposure to Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and Dengue Hospitalization in a Pediatric and Adolescent Population: A Nested Case-Control Post-Authorization Effectiveness Study
Thailand
EU PAS number:
EUPAS1000000218
First published:
20/03/2025
StudyOngoing
Initiation of Sodium-Glucose Cotransporter 2 inhibitors after first hospitalization for heart failure: a population-based cohort study
France
EU PAS number:
EUPAS1000000378
First published:
20/03/2025
StudyPlanned
A network meta-analysis of real-world studies comparing tofacitinib with other advanced therapies in the treatment of moderate-to-severe ulcerative colitis
United States
EU PAS number:
EUPAS108141
First published:
19/03/2025
StudyFinalised
Pregnancy and Infant Outcomes Following Exposure to PAXLOVID: A Post-Authorization Safety Study
United States
EU PAS number:
EUPAS106321
First published:
19/03/2025
StudyOngoing
Observational, multicentre, prospective, real-world post-authorization safety study describing the achievement of nintedanib-associated DIArrhoea control after 12 weeks of follow-up in patients with idiopathic puLmonary FIBrosis (IPF) and progressive pulmonary fibrosis (other than IPF) in Spain: the DIALFIB study
Spain
EU PAS number:
EUPAS106524
First published:
19/03/2025
StudyOngoing
An Observational Postauthorization Safety Study To Describe The Safety Of Ustekinumab and Other Biologic Treatments in a Cohort of Patients With Ulcerative Colitis or Crohn’s Disease Using Compulsory Swedish Nationwide Healthcare Registers and the Independent Swedish National Quality Register for Inflammatory Bowel Disease (SWIBREG) (Stelara UC/CD PASS (SWIBREG))
Sweden
EU PAS number:
EUPAS44885
First published:
19/03/2025
StudyOngoing
A Non-Interventional Multi-Database Post-Authorisation Study to Assess PregnancyRelated Safety Data from Women with SLE Exposed to Anifrolumab (ROSE PASS)
Denmark
Finland
France
Germany
United States
EU PAS number:
EUPAS108728
First published:
19/03/2025
StudyPlanned
Post-authorization safety study of iptacopan in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) using data from the non-interventional IPIG PNH Registry
Canada
China
France
Germany
Italy
Japan
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000457
First published:
17/03/2025
StudyOngoing
A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease (JINARC PASS)
Austria
Belgium
Finland
France
Germany
Italy
Luxembourg
Netherlands
Norway
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS12842
First published:
14/03/2025
StudyOngoing
LOWER: Lomitapide Observational Worldwide Evaluation Registry (AEGR-733-025)
Argentina
Austria
Canada
France
Greece
Italy
Netherlands
United Kingdom
United States
EU PAS number:
EUPAS5326
First published:
14/03/2025
StudyOngoing
An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
Austria
Belgium
Denmark
France
Greece
Netherlands
Norway
Russian Federation
Switzerland
United Kingdom
EU PAS number:
EUPAS19506
First published:
14/03/2025
StudyOngoing
The PRIDE-Asthma cohort: insight into the short- and long-term effects of asthma and asthma medication during pregnancy
Denmark
Netherlands
Norway
Sweden
EU PAS number:
EUPAS105750
First published:
14/03/2025
StudyOngoing
Clinical features of COVID-19 in Pediatric Patients (COPP-study)
Netherlands
EU PAS number:
EUPAS34743
First published:
14/03/2025
StudyPlanned
Alofisel-5003: An Observational Post-Marketing Registry on the Effectiveness and Safety of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistulas (INSPIRE)
Austria
Belgium
Czechia
Finland
France
Germany
Greece
Hungary
Ireland
Israel
Italy
Netherlands
Norway
Portugal
Romania
Slovakia
Slovenia
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS24267
First published:
14/03/2025
StudyOngoing
ERN eUROGEN registry
First published:
14/03/2025
Austria
Belgium
Croatia
Czechia
Denmark
Finland
France
Germany
Italy
Lithuania
Netherlands
Poland
Portugal
Spain
Sweden
Data source
Human
Congenital anomaly registryDisease registryENLIGHTEN: Assessment of quality improvement in the International Severe Asthma Registry
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000510
First published:
14/03/2025
StudyPlanned
LOOK-UP: Active pharmacovigilance study of the medicine Rinvoq™ (upadacitinib)
Portugal
EU PAS number:
EUPAS1000000227
First published:
14/03/2025
StudyFinalised
Non-Interventional Postmarketing Safety Study to Evaluate the COMIRNATY 2024-2025 Formula (monovalent KP.2) in the United States
United States
EU PAS number:
EUPAS1000000476
First published:
14/03/2025
StudyOngoing
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)
Brazil
Canada
Czechia
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
United States
EU PAS number:
EUPAS49827
First published:
14/03/2025
StudyOngoing
Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
United States
EU PAS number:
EUPAS45952
First published:
14/03/2025
StudyOngoing
Risk of Safety Events Among Patients with UC and PsA Treated with Tofacitinib and Other Advanced Treatments in the United States
United States
EU PAS number:
EUPAS103443
First published:
14/03/2025
StudyOngoing
Assessment of risk factors for Myocarditis in the United States (US) using Electronic Health Records and Claims data
United States
EU PAS number:
EUPAS104403
First published:
14/03/2025
StudyOngoing
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices (20150136)
Austria
Czechia
Finland
France
Germany
Greece
Italy
Netherlands
Poland
Portugal
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS17848
First published:
14/03/2025
StudyFinalised
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
United States
EU PAS number:
EUPAS45356
First published:
14/03/2025
StudyOngoing
DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications
Belgium
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000219
First published:
14/03/2025
StudyFinalised
Pharmacology Unit - Veneto Pharmacovigilance Centre (Pharmacol UNIVR), University Hospital Verona
Italy
First published:
13/03/2025
InstitutionEducational InstitutionHospital/Clinic/Other health care facilityENCePP partner
Post-marketing evaluation of the benefit-risk profile of originator biological drugs and biosimilars in the dermatological, rheumatological, gastroenterological and onco-hematological areas through the establishment of a single multiregional network for the integrated analysis of data from health databases, active surveillance and clinical registers - VALORE project
Italy
EU PAS number:
EUPAS43274
First published:
13/03/2025
StudyOngoing
Switch pattern of biological drugs (originator and biosimilars) for the treatment of chronic immune-mediated inflammatory diseases through an Italian network of regional administrative databases: the VALORE Project
Italy
EU PAS number:
EUPAS50139
First published:
13/03/2025
StudyFinalised
Identifying treatment discontinuation with biological drugs for immune-related inflammatory diseases using administrative healthcare data: a scoping review
Italy
EU PAS number:
EUPAS105336
First published:
13/03/2025
StudyPlanned